REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Stack Library

Hypertrophy Maximizer

Muscle Growthintermediate
47
Share
Peptides

3

Avg Daily mcg

1,407

Level

intermediate

Added

May 16, 2026

Overview

The Hypertrophy Maximizer is a precision-engineered peptide stack designed for intermediate users seeking accelerated lean muscle growth through synergistic growth hormone optimization and tissue repair. This three-peptide protocol combines the sustained GH-releasing action of CJC-1295 with the clean, ghrelin-mimetic pulses of Ipamorelin, while BPC-157 provides continuous connective tissue support and accelerated recovery between training sessions. CJC-1295, administered at 2000mcg three times per week, extends the half-life of endogenous growth hormone-releasing hormone, creating elevated baseline GH levels that persist for days rather than minutes. Ipamorelin at 300mcg daily delivers precise GH pulses without the appetite stimulation or cortisol elevation associated with other secretagogues, making it ideal for body composition goals. BPC-157 at 250mcg daily completes the stack by promoting angiogenesis, reducing inflammation, and supporting tendon and ligament integrity under heavy training loads. For optimal results, administer CJC-1295 on non-consecutive days (e.g., Monday, Wednesday, Friday) in the evening. Ipamorelin is best taken on an empty stomach, ideally 30 minutes before bed to coincide with natural GH secretion patterns. BPC-157 can be administered at any time but may be most effective when taken near the site of muscular strain or systemically in the morning. This stack is suited for intermediate trainees who have plateaued on natural programming and are looking to push past genetic set points in hypertrophy. Users should already have established nutrition protocols with adequate protein intake (1.6-2.2g/kg bodyweight) and progressive overload training programs. Research on GH secretagogue combinations suggests amplified pulsatile release when CJC-1295 and Ipamorelin are co-administered, while BPC-157 literature demonstrates enhanced recovery markers in musculoskeletal tissue models. A typical cycle runs 8-12 weeks followed by a 4-week break.

Dosing Protocol

CJC-1295

3 times per week

Read more about CJC-1295 →

2,000 mcg

per dose

300 mcg

per dose

250 mcg

per dose

Goals & Evidence

Evidence tier:community

Comments

Sign in to join the discussion

Disclaimer: This stack is community-submitted and for research purposes only. Peptide Contacts does not verify the safety or efficacy of submitted stacks. Always consult a qualified healthcare professional before using any peptide protocol.